Delivery Order SPE2DB20D3303-SPE2DB25FA3FY
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,814.08 to AmerisourceBergen Drug Corp for the supply of Yonsa 125 mg tablets (120-count units) under a firm fixed-price contract. The award was issued on September 2, 2025, with an ultimate completion date of September 23, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is performing the work at its corporate office location. This delivery order was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a $2,271.36 delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Yonsa 125 mg tablets (120 count). The contract is a firm fixed-price delivery order with a completion date of September 17, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Yonsa 125 mg tablets (120 count) with a ceiling value of $4,542.74. This is a firm fixed price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is to be completed by September 16, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Yonsa 125 mg tablets (120 count) valued at $2,271.36, with completion expected by October 2, 2025. This competitive award utilizes firm fixed pricing and is being performed at the company's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was awarded through open competition. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $4,542.74 to AmerisourceBergen Drug Corp for 120 tablets of Yonsa 125 mg, a pharmaceutical product. The contract, awarded on August 12, 2025, carries a firm fixed-price structure with an ultimate completion date of September 3, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order represents...
- The Defense Logistics Agency awarded a delivery order valued at $45,427.20 to AmerisourceBergen Drug Corp for the supply of Yonsa 125 mg tablets (120 count) with an ultimate completion date of September 16, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider,...
- The Defense Logistics Agency awarded a $6.81K delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Yonsa 125 mg tablets (120-count units). This is a firm fixed-price, non-set-aside delivery order with performance expected to conclude by September 30, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and...
- The Defense Logistics Agency awarded a $2,271.36 delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Yonsa 125 mg tablets (120 count). This is a firm fixed price, competitively awarded contract with no set-aside designation, scheduled for completion by September 23, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on May 1, 2025, for the supply of Yonsa 125 mg tablets (120-count units) valued at $2,271.36 with a firm fixed price structure. The order is scheduled for completion by May 22, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This is a non-set-aside competitive award issued as a delivery order under AmerisourceBergen's existing...
- The Defense Logistics Agency awarded a delivery order valued at $2,271.36 to AmerisourceBergen Drug Corp for the supply of Yonsa 125 mg tablets (120-count units). This contract, issued on March 18, 2025, with an ultimate completion date of April 8, 2025, operates under a firm fixed-price structure with no set-aside designation. The award represents a competitive procurement action, reflecting the vendor's established capability to meet federal pharmaceutical supply requirements....
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA3FYDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Yonsa 125 mg tablets (120 count) under a firm fixed-price contract type. The award, valued at $6.8K, was made on September 3, 2025, with an ultimate completion date of September 24, 2025. This non-competitive delivery order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary distribution operations. This delivery order represents a task executed under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. As a prime pharmaceutical vendor supporting the Defense Health Agency and other federal healthcare systems, AmerisourceBergen leverages this comprehensive global contract vehicle to supply a broad range of pharmaceutical products and medical commodities to military healthcare programs worldwide. The company's status as a major federal healthcare vendor, combined with its competitive positioning in the upcoming Pharmaceutical Prime Vendor Global Program Generation V contracts, underscores its critical role in supporting military medical supply chains.